Evidence map›Paper›PMID 40437613›Full record

ArticleDiagnostic pathology2025

Mutational analysis and protein expression of PI3K/AKT pathway in four mucinous cystadenocarcinoma of the breast.

Yan Zheng, Huaxiao Tang, Qian Liu, Yujie Zhang, Peng Zhao, Shukun Zhang, Chengqin Wang

Abstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan Zheng *Shandong Probincial Key Medical and Health Laboratory of Geriatric Gastrointestinal Tumor Pathology; Department of Pathology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.
Huaxiao Tang *Department of Pathology, the Affiliated Weihai Second Municipal Hospital of Qingdao University, Weihai, China.
Qian LiuShandong Probincial Key Medical and Health Laboratory of Geriatric Gastrointestinal Tumor Pathology; Department of Pathology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.
Yujie ZhangShandong Probincial Key Medical and Health Laboratory of Geriatric Gastrointestinal Tumor Pathology; Department of Pathology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China.
Peng ZhaoDepartment of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266000, China.
Shukun ZhangShandong Probincial Key Medical and Health Laboratory of Geriatric Gastrointestinal Tumor Pathology; Department of Pathology, Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China. zhangshukun0475@126.com.
Chengqin WangDepartment of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266000, China. wcq0879@126.com.

Funding

National Natural Science Foundation of China 81672606Natural Science Foundation of Shandong Province ZR2022MH206
6 · The paper itself

Abstract

introductionPrimary mucinous cystadenocarcinoma of the breast (BMCA) is a rare neoplasm with few reports in the literature. Its molecular characteristics, prognosis, and treatment protocols are not well understood, and there is a lack of consensus concerning the optimal management of this condition.

methodsFour cases of clinical and pathological data were collected from 2018 to 2024. Next generation sequencing with a 654 cancer-associated gene panel was utilized to detect gene mutations. Immunohistochemistry was carried out to evaluate protein expression levels.

resultsFirstly, we combined clinical imaging examinations and IHC to exclude the possibility of metastasis from ovarian or pancreatic origins. BMCA was composed of cystically dilated ducts lined by tall columnar mucin-containing epithelium. The morphological spectrum of MCA varied from MCA alone to MCA combined with carcinoma in situ (CIS) to MCA associated with invasive ductal carcinoma (IDC). ER/PR/HER2 and CK20 were all negative, while CK7 and GATA3 were positive by IHC in four cases. Although the prognosis of the other three patients was favorable during the follow-up periods of 13, 10, and 3 months, respectively, case 2# experienced a recurrence of the primary focus after 42 months. No lymphatic metastasis was identified in cases 1-4#. In addition, next-generation sequencing (NGS) identified 17 mutated genes and 25 mutation sites in four cases. TP53, PIK3CA, AKT, PTEN, and RB1 were the highest frequency mutated genes. Given that AKT mutations typically refer to AKT1(E17K) rather than AKT2 or AKT3, AKT protein expression was detected only in Case 2# (AKT1, E17K). PTEN protein was expressed in case 4# (corresponded to missense mutation), loss of PTEN expression were corresponding with splicing mutation in case1#. In brief, AKT and PTEN protein expression could be corresponded to gene mutation in a certain extent. However, PIK3CA protein expression was positive in Case 2# but negative in Case 1#, which did not fully accordance with the NGS-detected missense mutations. No associated germline variations were detected. Additionally, neither PDL-1 expression nor microsatellite instability-high (MSI-H) status was identified.

conclusionThe tumorigenesis and development of BMCA may be regulated to the PI3K/AKT pathway. Consequently, a comprehensive genetic analysis of more cases could elucidate the molecular mechanisms underlying this rare tumor.

Indexed as

Biomarkers, TumorBreast NeoplasmsCystadenocarcinoma, MucinousPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAdultAgedDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryMiddle AgedMutationSignal TransductionBiomarkers, TumorPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAKTBreast cancerMucinous cystadenocarcinomaPI3K/AKT pathwayPIK3CAPTEN

Identifiers

PMID40437613
PMCPMC12121189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.